BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
Read original at benzingaStocks · News reference
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 6:29 PM
- Checked
- Aug 13, 2026, 6:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — BeyondSpring Inc. (BYSI)
Filed: 2026-08-14 AccNo: 0001171843-26-005557 Size: 316 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
Read original at benzingaWhy Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
Read original at benzinga